Propeller collaborates with GSK to develop a digital sensor for the Ellipta inhaler
Collaboration reinforces Propeller Health's leadership in respiratory digital health and creates a joint opportunity to advance the treatment of respiratory disease through digital innovation
Propeller Health, provider of an FDA-cleared digital health solution for improving outcomes in asthma and chronic obstructive pulmonary disease (COPD), has announced a development agreement and R&D collaboration with GSK for its Ellipta inhaler, the pharmaceutical company's innovative, patented, dry powder inhaler.
Under the terms of this non-exclusive agreement, the first between the two companies, Propeller Health will develop and manufacture a custom sensor for the Ellipta inhaler for use in certain GSK clinical studies in asthma and COPD.
In the studies, the sensor will automatically collect and record data on the inhaler's usage (date and time of each use), wirelessly transmitting the information to a central data repository for analysis by GSK's clinical researchers. The sensor technology will be used to provide greater insights into adherence patterns across patient populations and may allow for more precise correlation of adherence with safety, efficacy and economic outcomes.
‘We are pleased to announce a collaboration with GSK, a global leader in the treatment of respiratory disease. Together we aim to combine our expertise to empower patients and positively impact care,’ said David Van Sickle, CEO and co-founder of Propeller.
Dave Allen, Senior Vice President of Respiratory R&D at GSK, said: ‘We continue to find new and better ways to conduct clinical trials by exploring novel patient centred outcomes through strategic collaborations. Using innovative sensor technology to improve the quality of adherence data collected during our studies will advance our understanding of disease and inform our decision making in the development of new medicines.’
Propeller creates a custom view of each patient, allowing them and their physicians to better understand the impact and management of their disease in daily life. To date, the Propeller platform has received FDA 510(k) class II clearance to measure and improve medication adherence, help predict exacerbations, and help reduce the frequency of symptoms and exacerbations in asthma and COPD.
